{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:20:14Z","timestamp":1762946414843,"version":"3.45.0"},"reference-count":31,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Rotavirus (RV) continues to be the leading cause of acute gastroenteritis (AGE) globally among children under five. National RV vaccination efforts have lowered morbidity and mortality. Vaccination is a key public health tool to alleviate this substantial burden of RV in middle- and low-income countries. In Syria, RV morbidity accounts for 27% of severe GE. We conducted a cost-effectiveness analysis of introducing rotavirus vaccinations (RVV) into Syria\u2019s National Immunization Program. Methods: A decision tree model was developed to assess the cost-saving of two-dose rotavirus vaccinations (Rotarix\u00ae) compared to no vaccination. A birth cohort of 573,944 newborns was simulated throughout a 5-year time frame to capture the near-term health and economic effects. The analysis adopted an incremental cost-saving approach, evaluating a hypothetical 2023 birth cohort from the government\u2019s perspective. Outcomes included the cost per disability-adjusted life year (DALY) prevented and the cost per death averted. Model inputs were derived from local data, specifically including healthcare and vaccination costs and deaths attributable to RVGE, the scientific literature, and national\/international databases. The incremental cost-effectiveness ratio (ICER) measures the cost of avoiding one disability-adjusted life year (DALY) adopted. Results: Over five years, the two-dose RV strategy would avert 77,500 RVGE cases, reduce outpatient visits by 59%, and reduce severe RV hospitalizations by 41%. The vaccination program would cost $21,817,918 USD and avert $3,239,907 USD in healthcare costs, resulting in a net cost of $18,578,011 USD. The incremental cost-effectiveness ratio (ICER) was $2098 USD per DALY averted, which is below three times Syria\u2019s GDP per capita ($753.6 USD), indicating high cost-effectiveness according to WHO benchmarks. Conclusions: Introducing rotavirus vaccination is highly cost-saving and will result in a substantial reduction in healthcare burdens and lives lost. Policy planners must ensure its inclusion in the National Immunization Programs, ensuring sustainable financing and equitable access.<\/jats:p>","DOI":"10.3390\/vaccines13111157","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T10:56:47Z","timestamp":1762945007000},"page":"1157","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness Analysis of Universal Rotavirus Vaccination Schedules in Syria"],"prefix":"10.3390","volume":"13","author":[{"given":"Mania","family":"Mershed","sequence":"first","affiliation":[{"name":"Department of Research, MOH, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razan","family":"Altarabishi","sequence":"additional","affiliation":[{"name":"Department of Primary Health Care, MOH, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Research, MOH, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamia","family":"Abu ajaj","sequence":"additional","affiliation":[{"name":"Department of Primary Health Care, MOH, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dima","family":"Alrashee","sequence":"additional","affiliation":[{"name":"Department of Health Economy, MOH, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manar","family":"Kamel","sequence":"additional","affiliation":[{"name":"Department of Health Economy, MOH, Damascus, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5112-3893","authenticated-orcid":false,"given":"Salah","family":"Al Awaidy","sequence":"additional","affiliation":[{"name":"Freelance Public Health Consultant, Muscat 111, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(24)00691-1","article-title":"Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990\u20132021, for 204 countries and territories: A systematic analysis for the Global Burden of Disease Study 2021","volume":"25","author":"Kyu","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12985-022-01898-9","article-title":"Global burden and trends of rotavirus infection-associated deaths from 1990 to 2019: An observational trend study","volume":"19","author":"Du","year":"2022","journal-title":"Virol. J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Karampatsas, K., Osborne, L., Seah, M.L., Tong, C.Y.W., and Prendergast, A.J. (2018). Clinical characteristics and complications of rotavirus gastroenteritis in children in east London: A retrospective case-control study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194009"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1016\/j.vaccine.2021.10.003","article-title":"The economic burden of rotavirus hospitalization among children <5 years of age in selected hospitals in Bangladesh","volume":"39","author":"Ahmed","year":"2021","journal-title":"Vaccine"},{"key":"ref_5","unstructured":"Preedy, V.R., and Watson, R.R. (2010). The Economic Burden of Rotavirus Diarrhea: Taiwan Perspectives. Handbook of Disease Burdens and Quality of Life Measures, Springer. Available online: https:\/\/link.springer.com\/referenceworkentry\/10.1007\/978-0-387-78665-0_71."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2276619","DOI":"10.1080\/21645515.2023.2276619","article-title":"Cost-of-illness of gastroenteritis caused by rotavirus in Chinese children less than 5 years","volume":"19","author":"Fu","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14712598.2021.1977279","article-title":"Rotavirus vaccines: Progress and new developments","volume":"22","author":"Cates","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/cid\/civ1013","article-title":"World Health Organization\u2013Coordinated Global Rotavirus Surveillance Network. Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000\u20132013","volume":"62","author":"Tate","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1016\/j.vaccine.2017.05.087","article-title":"Impact and cost-effectiveness of rotavirus vaccination in Bangladesh","volume":"35","author":"Pecenka","year":"2017","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1016\/j.vaccine.2022.07.044","article-title":"Cost-effectiveness of rotavirus vaccination in Mozambique","volume":"40","author":"Chissaque","year":"2022","journal-title":"Vaccine"},{"key":"ref_11","unstructured":"World Health Organization (2024, December 21). Immunization, Vaccines and Biologicals: Rotavirus. Available online: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases\/rotavirus."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Thobari, J.A., Watts, E., Carvalho, N., Haposan, J.H., Clark, A., Debellut, F., Mulyadi, A.W.E., Sundoro, J., Nadjib, M., and Hadinegoro, S.R. (2025). Cost effectiveness analysis of rotavirus vaccination in Indonesia. Vaccine, 43.","DOI":"10.1016\/j.vaccine.2024.126478"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1093\/infdis\/jix175","article-title":"Approaches to Vaccination Among Populations in Areas of Conflict","volume":"216","author":"Nnadi","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(13)60222-6","article-title":"Global burden of childhood pneumonia and diarrhoea","volume":"381","author":"Walker","year":"2013","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1664","DOI":"10.1016\/S2214-109X(19)30439-5","article-title":"Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: A modelling study","volume":"7","author":"Debellut","year":"2019","journal-title":"Lancet Glob. Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jpids\/piab114","article-title":"Tate\u2014Global Estimates of Rotavirus Hospitalizations Among Children Below 5 Years in 2019 and Current and Projected Impacts of Rotavirus Vaccination","volume":"11","author":"Hallowell","year":"2022","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5005\/jp-journals-11002-0014","article-title":"Rotavirus Infection in Neonates and Young Infants","volume":"1","author":"Shakya","year":"2022","journal-title":"Newborn"},{"key":"ref_18","unstructured":"(2024, August 10). Rotarix\u00ae Vaccine Efficacy. CDC, Available online: https:\/\/www.cdc.gov\/vaccines\/vpd\/rotavirus\/hcp\/about-vaccine.html#:~:text=Vaccine%20Effectiveness%20and%20Duration%20of%20Protection,RotaTeq%C2%AE%20(RV5&text=Two%20clinical%20trials%20found%20Rotarix,hospitalizations%20through%20two%20rotavirus%20seasons."},{"key":"ref_19","unstructured":"(2025, April 08). Rotavirus Vaccines: WHO Position Paper\u2014July 2021. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-WER9628."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMoa0904797","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"362","author":"Madhi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_21","unstructured":"(2024, April 03). Rotavirus Vaccine (RV) Price Data UNICEF. Available online: https:\/\/www.unicef.org\/supply\/documents\/rotavirus-vaccine-rv-price-data."},{"key":"ref_22","unstructured":"Gavi (2024, August 10). Rotavirus Vaccine Cost Calculator for Gavi-Eligible Countries. Available online: https:\/\/www.path.org\/our-impact\/resources\/rotavirus-vaccine-cost-calculator\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1016\/j.vaccine.2022.05.042","article-title":"Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis","volume":"40","author":"Janko","year":"2022","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1016\/j.vaccine.2013.10.022","article-title":"Cost-Effectiveness of a new Rotavirus Vaccination Program in Pakistan: A Decision Tree Model","volume":"31","author":"Patela","year":"2013","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Van Hoek, A.J., Ngama, M., Ismail, A., Chuma, J., Cheburet, S., Mutonga, D., Kamau, T., and Nokes, D.J. (2012). A Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison between Rotarix and RotaTeq Vaccines. PLoS ONE, 7.","DOI":"10.1371\/annotation\/6b9d910e-4c85-41ca-ae56-b5996e81820a"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1086\/431513","article-title":"Projected cost effectiveness of rotavirus vaccination for children in Asia","volume":"192","author":"Podewils","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_27","unstructured":"WHO (2024, April 03). New COST-Effectiveness Updates from WHO-CHOICE. Available online: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/new-cost-effectiveness-updates-from-who-choice."},{"key":"ref_28","first-page":"e1508","article-title":"Challenges of calculating cost-effectiveness thresholds","volume":"11","author":"Claxtonb","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"hta19140","DOI":"10.3310\/hta19140","article-title":"Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold","volume":"19","author":"Claxton","year":"2015","journal-title":"Health Technol. Assess."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research","volume":"19","author":"Woods","year":"2016","journal-title":"Value Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.vhri.2023.02.006","article-title":"Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece","volume":"36","author":"Tzanetakos","year":"2023","journal-title":"Value Health Reg. Issues"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1157\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:16:10Z","timestamp":1762946170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/11\/1157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["vaccines13111157"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13111157","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}